Enorama Pharma AB
The answer first
Does Enorama Pharma beat the market?
No, Enorama Pharma has not beaten the market over the last year.
Max for seven days
Follow Enorama Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Enorama Pharma
Your first answer is free, no account needed.
Do you own Enorama Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Enorama Pharma and a few more. Free, no card.
Super Stock+44.6%In short
- Enorama Pharma has fallen 79.3% over the past year, including dividends.
- The largest fall over the past three years was 96.8%. The price is 99.6% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns0.21
- Return on equityProfit divided by equity−118.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 197 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equitynegative earnings
- P/SPrice divided by sales26.5
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 108 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−44.2%
- 6 months+33.0%
- 9 months−16.1%
- 12 months−79.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Enorama Pharma
One fund we follow owns Enorama Pharma. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Enorama Pharma
Enorama Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells tobacco-free white snus in Sweden. It offers its products under the NIC-S brand name. The company was incorporated in 2006 and is based in Stockholm, Sweden.


See the full analysis of Enorama Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card